The weight-loss drug race seems to be less about the obvious (shedding pounds) and more about a fleshed-out medical land grab.
What began with stellar demand for GLP-1s is now spreading into adjacent healthcare verticals like sleep apnea, heart disease, and more. The prize is a market worth more than $150 billion.
Pharma giants are now racing to diversify beyond diabetes and obesity, and in doing so, this week, one heavyweight just made a massive statement.
💵💰Don't miss the move: Subscribe to TheStreet's free daily newsletter💰💵
It wasn’t just a lab win for the healthcare giant, but it was a real-world study, which comes from a brand that’s already a dominant player in the niche. And now, it might have gotten a critical edge in the race for long-term medical relevance.
GLP-1 market explodes as competition widens
GLP-1 weight-loss drugs continued their fine form this year, with market forecasts suggesting that the market’s surge is just getting started.
For instance, Goldman Sachs forecasts the space could reach $95 billion by 2030, while Morgan Stanley sees a path to $150 billion by 2035.
Related: Temu’s US shoppers just caught a massive break from Trump’s tariff heat
Moreover, the weight-loss segment alone is set to rise from $21 billion in 2025 to $49 billion by 2030.
That said, here are some of the key players that are dominating the space:
- Eli Lilly LLY: Zepbound (obesity), Mounjaro (type 2 diabetes)
- Novo Nordisk NVO: Wegovy (obesity), Ozempic (type 2 diabetes)
- Amgen: AMG-133 (maridebartide)
- Roche: CT-388 (through the Carmot acquisition)
- Pfizer: oral danuglipron
- Viking Therapeutics: VK2735
Also, distributors and telehealth plays like Hims & Hers have cashed in on the surge big time.
For perspective, it just guided for $2.3–$2.4 billion in 2025 sales, with a whopping $725 million tied to GLP-1s. Q2 alone saw $190 million in GLP-1 sales across its 2.4 million subscribers.
Use cases are also widening.
Zepbound, for instance, became the first GLP-1 approved drug for treating sleep apnea last December.
Moreover, trials are underway that target kidney, liver, and heart failure, broadening the market substantially.
Weight-loss drug Wegovy shows major edge in heart health data
Novo Nordisk just landed a massive win in its head-to-head battle with Eli Lilly in the weight-loss drug space.
In a new real-world study, Novo’s Wegovy helped in lowering the risk of major cardiovascular events by more than 50% in comparison to Lilly’s Zepbound (tirzepatide), for those patients suffering from obesity and heart disease but without diabetes.
The company cited its STEER study, pulling data from over 20,000 U.S. adults aged 45+ with cardiovascular disease but without a history of diabetes, recorded in the U.S. Komodo Research database from 2016 to 2024.
Related: JetBlue’s AI move could solve a massive problem for passengers
The data indicated that Wegovy’s active ingredient, semaglutide 2.4 mg, lowered the risk of heart attack, stroke, or death from any cause by 57% in patients who were on the drug continuously.
Even when accounting for treatment gaps, Wegovy delivered a sizeable 29% risk reduction across all treated patients.
“This data confirms that semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes,” said Ludovic Helfgott, Novo’s head of Product & Portfolio Strategy.
The breakthrough results were shown at the European Society of Cardiology Congress on Sunday.
It’s important to note that Wegovy is already approved in the U.S. and EU to reduce major heart event conditions in overweight or obese adults suffering from cardiovascular troubles.
Novo vs. Lilly: where the weight-loss race stands
In the U.S., Lilly’s Zepbound (tirzepatide) has had the decisive lead in total obesity prescriptions for the better part of 2025.
However, since May, Wegovy (semaglutide) has clawed back share with new Wegovy Rx rising 33% following the FDA’s compounding ban, and the weekly TRx gap narrowed from 175,000 (May 23) to 133,000 (Jul 18), as per IQVIA data.
It’s important to note that Zepbound booked a massive $3.38 billion in U.S. sales in Q2 2025 (up 172% year-over-year), strengthening Lilly’s current script lead, which translated into real dollars.
Wegovy generated a whopping $5.78 billion in sales in the first half of 2025, driving Novo’s obesity-care H1 to $6.08 billion roughly (amounts reflect DKK-to-USD conversion based on the August 29, 2025, exchange rate).
More News:
- Jim Cramer says this red-hot health care stock still has plenty of room to run
- Tesla just got its biggest break yet in the robotaxi wars with a key permit
- Starbucks' behind-the-scenes shift hints at brewing struggles
Moreover, though the data shows Zepbound claimed top honors on U.S. volume with access expanding along with physician enthusiasm for the dual GIP/GLP-1, Wegovy’s recovery has been impressive.
Also, with new use-cases for Wegovy, Novo could potentially improve payer coverage and tilt prescriber preference in high-risk patients.
Hence, the next 2–3 quarters effectively hinge on coverage wins, supply reliability, and outcomes-based labeling across both franchises.
Related: Coca-Cola selling big coffee brand it bought to take on Starbucks
